logo
Alberta working with oil companies on pipeline proposal, Danielle Smith says

Alberta working with oil companies on pipeline proposal, Danielle Smith says

Alberta Premier Danielle Smith says her government is working with oil companies to try and secure a proposal for a new pipeline to the west coast – and says she expects Prime Minister Mark Carney to 'operate in good faith' on the pipeline issue.
The Alberta government has also pitched Mr. Carney on a kind of quid pro quo, in which oil companies commit to building the Pathways carbon capture project if he greenlights an oil pipeline.
Oil and gas pipelines have come into sharp focus in the wake of President Donald Trump's trade war, as Canada's fossil fuel sector searches for more opportunities to diversify itself from the United States, its largest customer.
Mr. Carney has also pledged to make Canada into an energy superpower, but Ms. Smith says meeting that goal will rely on new pipelines that can transport Alberta oil and gas to a Canadian coast –west, north or east – for access to overseas markets.
British Columbia's Energy Minister, Adrian Dix, recently shut down the idea of a new pipeline in the province, citing the impracticality and massive costs associated with such a proposal.
But Ms. Smith told the Global Energy Show in Calgary on Wednesday that she's confident she can convince the province's premier, David Eby, of the merits of an oil pipeline.
'We're doing what we can to address the legitimate concerns that we heard,' Ms. Smith said.
'What I've heard them say recently is there's no project - no project and no proponent. Well, that's my job. There will be soon. We're working very hard on being able to get industry players, private-sector players, to realize this time might be different.'
Ms. Smith said there may be a consortium of companies interested in joining forces to build a pipeline. If so, she said Alberta would work with the group to test out Mr. Carney's promised two-year approval process for major infrastructure projects.
'We know that it's a chicken-and-egg problem, that no one's going to come forward with a project without some guarantee that's going to be approved,' she said. 'The Prime Minister, I want to take him at his word that he wants to operate in good faith. So we're going to operate in good faith.'
The ultimate goal is to get an oil pipeline onto a list of major infrastructure projects being developed by the federal government. Ms. Smith said she also wants to see the Pathways Alliance carbon capture project on that list.
The Pathways Alliance is a consortium of Canada's six largest oil sands companies, which together have publicly committed to reaching net-zero greenhouse gas emissions from oil sands production by 2050.
At the heart of the group's pledge is a 400-kilometre-long pipeline that would transport carbon captured at oil sands facilities to an underground hub near Cold Lake, Alta., reducing emissions by 22 megatonnes a year.
The project could cost anywhere from $10-billion to $20-billion – an amount that's all expense, because there is no revenue associated with it, Ms. Smith said.
'But if you couple it with a million barrel-per-day pipeline, that allows you $20-billion worth of revenue year after year after year for the lifetime of that project. All of a sudden, a $10-billion to $20-billion cost to decarbonize looks a lot more attractive when you have a new source of revenue.'
Ms. Smith said she doesn't believe it would be problematic to fill a new pipeline, given that Enbridge recently announced an open season on its Flanagan South pipeline expansion to the U.S. for 100,000 barrels, and drew 400,000 barrels of interest.
'What we are hearing from the energy sector is: Build it, they will come.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hotel boom igniting tourism and economic growth in Ottawa, experts say
Hotel boom igniting tourism and economic growth in Ottawa, experts say

CTV News

timean hour ago

  • CTV News

Hotel boom igniting tourism and economic growth in Ottawa, experts say

The Alt Hotel at the Ottawa Airport is expected to make its launch in fall 2025. (Kimberley Fowler/CTV News Ottawa) The City of Ottawa is gearing up for a hotel boom over the next several years. Five major international hotel brands are expanding in the city, putting Ottawa on track to become a premier Canadian destination for tourists and business. AC Hotel by Marriott Ottawa Downtown opened on Rideau Street in April. The location is ideal for travellers staying and exploring the heart of the city. Two other Marriott-branded hotels are coming to Ottawa. The Moxy Ottawa downtown is expected to open in the ByWard Market in 2026, followed by a Renaissance Hotel opening on Slater Street in 2027. The grand opening of the highly anticipated Hard Rock Hotel and Casino at the Rideau Carleton Raceway is on July 3, and in the fall of 2025 The Alt Hotel Ottawa Airport is expected to make its launch, designed with a connection directly into the airport's terminal. Hard Rock Hotel and Casino The future Hard Rock Hotel and Casino in Ottawa is set to open July 3, 2025. (Kimberley Fowler/CTV News Ottawa) 'It's great news when we have investors decide to choose Ottawa for their investments,' says Jérôme Miousse, Ottawa Tourism director of public affairs. 'That's a good show of confidence in our destination and it's an even better show of confidence in our local economy.' Alex Forrester is visiting Ottawa for a conference and brought his family along for a mini vacation. 'Typically, with children, we are staying at hotels,' says Forrester. 'We're staying at the Fairmont, so it's a short walk to everything downtown, which has been convenient for us.' Alexander Thomas, visiting from the UK, used websites to help him find the perfect place to stay while in the capital. 'On we got the option to see the map which is close to the attractions. So, I liked that. I booked the hotel,' he said. Local businesses are also excited for the boom, especially as the city continues to rebuild after the pandemic. 'We're now back to more or less normal levels of tourism and we are growing. We're now looking at growing our tourism, our visitor's industry, and hotels are aware,' says Miousse. With the Hard Rock's brand recognition and The Alt Hotel's proximity to the airport, Miousse says, 'It's really good for business in general because it just brings people out there to enjoy the surroundings of these hotels as well.' The new hotels also support the city's goal of growing conference and corporate events, with amenities tailored to business and leisure travellers.

Barrie council backs $375M south-end multi-use complex after some tweaks to the plan
Barrie council backs $375M south-end multi-use complex after some tweaks to the plan

CTV News

timean hour ago

  • CTV News

Barrie council backs $375M south-end multi-use complex after some tweaks to the plan

A sign for the future home of the south Barrie mixed-use Recreation Complex and Library. Barrie city councillors took another step forward with plans for a $375 million south-end recreation and library complex at Wednesday night's meeting, but not without making a few tweaks first. While most of the changes were modest, a few stood out, particularly a decision to scale back the size of the library component. The facility, which will eventually be built on a 100-acre site along McKay Road East, is being described by councillors as a game-changer for the city's fast-growing south-end. The centre will include a quad-pad arena, an eight-lane 25-metre swimming pool, therapy pools, a triple gymnasium, a fitness centre, and multi-purpose rooms. 'I just wanted to emphasize how well received this has been in south-end Barrie," said Councillor Bryn Hamilton during the meeting. Library Space One of the more notable amendments saw the planned library space reduced from 45,000 square feet to 30,000 square feet. Council also directed staff to explore shared-use options for certain amenities, like washrooms, rather than constructing separate facilities for rec centre workers. Councillor Sergio Morales said the reduction wasn't a statement on the importance of library services overall. 'Just because we're reducing here specifically, it's not indicative of library need in general.' Sports Hall of Fame Another amendment will establish a permanent space inside the complex for Barrie's Sports Hall of Fame, currently housed at the Sadlon Arena. Councillor Gary Harvey supported the move, saying it would have more exposure at the new site. 'It's going to have a lot more foot traffic than what the Sadlon [Arena] will ever see.' Housing Development Council also gave the green light to a related housing development in the south end, rezoning a property near Essa Road and Mapleview Drive to allow for 458 street and block townhouse units, with an additional 66 optional dwellings for future purchasers. The revised proposal was given council's stamp of approval after a troubled first pitch. 'The first application was basically creating a small city within one stretch of about 25-acres,' said Harvey. 'Thankfully, a new applicant came in, but I think this is going to be a very positive addition to the area, opposed to having an empty field or a driving range at this location.' The recreational complex and all its amenities were passed by council, with construction still years away.

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

Globe and Mail

timean hour ago

  • Globe and Mail

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store